An Open Label Study of GBT440 to Evaluate the Effect on Oxygenation in Healthy Subjects at Rest and Maximal Exercise Under Hypoxic Conditions

Trial Profile

An Open Label Study of GBT440 to Evaluate the Effect on Oxygenation in Healthy Subjects at Rest and Maximal Exercise Under Hypoxic Conditions

Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs Voxelotor (Primary)
  • Indications Hypoxia; Idiopathic pulmonary fibrosis; Sickle cell anaemia
  • Focus Proof of concept; Therapeutic Use
  • Acronyms Basecamp Study
  • Sponsors Global Blood Therapeutics
  • Most Recent Events

    • 23 May 2018 Results investigating the effect of GBT440, an allosteric modulator of hemoglobin, on hypoxic exercise in healthy subjectspresented at the 114th International Conference of the American Thoracic Society
    • 23 May 2018 Results investigating the effect of GBT440, an allosteric modulator of hemoglobin, on hypoxic exercise in healthy subjectspresented at the 114th International Conference of the American Thoracic Society
    • 07 May 2018 According to a company media release, results from this study will be preasented at the upcoming American Thoracic Society Conference 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top